Physician
Hematology
Dr. Apostolia M. Tsimberidou, MD
|
|
Give Review
Apostolia Tsimberidou is an expert in the field of Hematology. Apostolia M. Tsimberidou, MD is a published doctor. He published 89 publications, including: 'Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.' Apostolia Tsimberidou is registered with Medicare.
Publications
- Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.
- P5.01A first in human, dose escalation trial of MSC2363318A - a dual p70S6K/Akt inhibitor, for patients with advanced malignancies.
- Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer.
- Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
- Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
- Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I clinic.
- Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.
- Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic.
- A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer.
- Triple Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents.
- Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials.
- Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of...
- Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.
- Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses.
- First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors.
- Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies.
- Characteristics and survival of patients with advanced cancer and p53 mutations.
- Impact of MicroRNAs in Resistance to Chemotherapy and Novel Targeted Agents in Non-Small Cell Lung Cancer.
- Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing.
- Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.
- Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms.
- Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program.
- MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study.
- Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.
- Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus.
- Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies.
- A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia.
- Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer.
- Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors.
- Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases.
- Barriers to Study Enrollment in Patients With Advanced Cancer Referred to a Phase I Clinical Trials Unit.
- Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA mutations.
- Combining Erlotinib and Cetuximab is Associated with Activity in Patients with Non Small Cell Lung Cancer (including Squamous Cell Carcinomas) and Wild-Type EGFR or Re...
- Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer.
- A pilot study of temsirolimus and body composition.
- Body composition and survival in the early clinical trials setting.
- Anti-vascular endothelial growth factor therapy in the era of personalized medicine.
- Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Synd...
- P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy.
- A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intraVenous gemcitabine and bevacizumab for patients with advanced cancers and predo...
- Biomarker-Directed Therapy of Squamous Carcinomas of the Head and Neck: Targeting PI3K/PTEN/mTOR Pathway.
- Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer.
- PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
- Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver.
- Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy.
- Advance Care Planning in Patients With Cancer Referred to a Phase I Clinical Trials Program: The MD Anderson Cancer Center Experience.
- Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs.
- Intraperitoneal and intraVenous chemotherapy in peritoneal carcinomatosis.
- Outcomes in 144 Patients With Colorectal Cancer Treated in a Phase I Clinic: the MD Anderson Cancer Center Experience.
- Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience.
- Evaluation of the Clinical Relevance of Body Composition Parameters in Patients With Cancer Metastatic to the Liver Treated With Hepatic Arterial Infusion Chemotherapy.
- Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience.
- Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center.
- Cardiovascular Toxicity Profiles of Vascular-Disrupting Agents.
- Inhibition of the Ras/Raf/MEK/ERK and RET Kinase Pathways with the Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib ...
- Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience.
- PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
- PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers.
- Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic.
- Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement.
- A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tu...
- Epstein-Barr virus latent membrane protein 1 mRNA is expressed in a significant proportion of patients with chronic lymphocytic Leukemia.
- Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience.
- Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?
- Pediatric therapy-related myelodysplastic syndrome/Acute myeloid leukemia: the MD Anderson Cancer Center experience.
- Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience.
- A phase I clinical trial of darinaparsin in patients with refractory solid tumors.
- Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience.
- The prognostic significance of cytokine levels in newly diagnosed Acute myeloid leukemia and high-risk myelodysplastic syndromes.
- Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's Syndrome or fludarabine-refractory chronic lymph...
- Assessment of chronic lymphocytic Leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of ...
- Detection of Richter's transformation of chronic lymphocytic Leukemia by PET/CT.
- Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone.
- Myeloid sarcoma involving the gynecologic tract: a report of 11 cases and review of the literature.
- Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center.
- Potential curability of newly diagnosed Acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid.
- Fludarabine and mitoxantrone for patients with chronic lymphocytic Leukemia.
- Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alte...
- Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
- Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabi...
- Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy.
- Strategies to Overcome Clinical, Regulatory, and Financial Challenges in the Implementation of Personalized Medicine.
- FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors.
- Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer.
- MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors.
- Precision cancer medicine: the future is now, only better.
- Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance.
- Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Coagulation Disorders (incl. Hemophilia)
- View All
Doctors Specialties
- Hematology
Accepted Insurances
- Blue Card PPO
- Blue Choice
- Great West Healthcare-Cigna PPO
- First Health (Coventry Health Care) PPO
- Choice Care PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1730374661 | |
| NPPES Provider LastName | TSIMBERIDOU | |
| NPPES Provider FirstName | APOSTOLIA | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 227.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1730374661 |
| Last Name Of The Provider | TSIMBERIDOU |
| First Name Of The Provider | APOSTOLIA |
| View All |
Similar Doctors
|
|
Dr. Modupe Idowu, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sheeba K. Thomas, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Harinder S. Juneja, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven M. Kornblau, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Loretta J. Nastoupil, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kanwal P. Raghav, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer Wang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nitin Jain, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Zahida Yasin, MD
This Doctor is OpenDoctor Recommended.
|